Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug tame hepatitis e? a first human trial begins

NCT ID NCT07728487

Disease control Sponsor: Atea Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called AT-587 in healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for hepatitis E, a liver infection that currently has no approved therapy. Participants receive either AT-587 or a placebo, and researchers monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called AT-587
What this could lead to
If safe and effective, AT-587 could become a treatment option for hepatitis E, a liver infection with no approved therapy.
What could go wrong
This is a very early Phase 1 trial in healthy people, so it does not yet test whether the drug works against the virus. Side effects may emerge.
Why investors are watching

ATEA Pharmaceuticals is running a phase 1 trial of AT-587, its first-in-human drug, in 62 healthy adults. The study checks whether the drug is safe and how the body processes it. For a small company with few products, this early readout is a key test of whether AT-587 has a future.

If it works: If the drug proves safe and well-tolerated, ATEA can move it into later trials, which may support the company's pipeline and value. A positive result could also attract partners or funding for further development.

If it fails: Phase 1 trials often fail or show safety problems, and a negative result could halt AT-587's development. A delay or unclear data could also hurt the company's prospects, since it has few other assets to fall back on.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index (BMI) of 18-29 kg/m2 * Must agree to use protocol-specified methods of contraception * Negative pregnancy test * Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: * Pregnant or breastfeeding * Abuse of alcohol or drugs * Use of other investigational drugs within 30 days of dosing * Other clinically significant medical conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis E are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis E virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis E

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atea Study Site

    RECRUITING

    Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.